A Case of a Malignant Lymphoma Patient Persistently Infected with SARS-CoV-2 for More than 6 Months
Abstract
:1. Introduction
2. Materials and Methods
2.1. Saliva and Nasopharyngeal Reverse Transcription Polymerase Chain Reaction (RT-PCR) Testing
2.2. Serological Testing for SARS-CoV-2 Antibody
2.3. SARS-CoV-2 Whole Viral Sequencing and Phylogenetic Analysis
2.4. SARS-CoV-2 Viral Infectivity Studies
3. Case
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020, 584, 430–436. [Google Scholar] [CrossRef] [PubMed]
- Tenforde, M.W.; Patel, M.M.; Ginde, A.A.; Douin, D.J.; Talbot, H.K.; Casey, J.D.; Mohr, N.M.; Zepeski, A.; Gaglani, M.; McNeal, T.; et al. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin. Infect. Dis. 2022, 74, 1515–1524. [Google Scholar] [CrossRef] [PubMed]
- Langerbeins, P.; Hallek, M. COVID-19 in patients with hematologic malignancy. Blood 2022, 140, 236–252. [Google Scholar] [CrossRef] [PubMed]
- Leung, W.F.; Chorlton, S.; Tyson, J.; Al-Rawahi, G.N.; Jassem, A.N.; Prystajecky, N.; Masud, S.; Deans, G.D.; Chapman, M.G. COVID-19 in an immunocompromised host: Persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: A case report. Int. J. Infect. Dis. 2022, 114, 178–182. [Google Scholar] [CrossRef]
- Choi, B.; Choudhary, M.C.; Regan, J.; Sparks, J.A.; Padera, R.F.; Qiu, X.; Solomon, I.H.; Kuo, H.H.; Boucau, J.; Bowman, K.; et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 2020, 383, 2291–2293. [Google Scholar] [CrossRef]
- Prevenstion CfDCa. Isolation and Precaution for People with COVID-19; CDC: Atlanta, GA, USA, 2022. [Google Scholar]
- Lee, J.S.; Goldstein, J.M.; Moon, J.L.; Herzegh, O.; Bagarozzi, D.A., Jr.; Oberste, M.S.; Hughes, H.; Bedi, K.; Gerard, D.; Cameron, B.; et al. Analysis of the initial lot of the CDC 2019-Novel Coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. PLoS ONE 2021, 16, e0260487. [Google Scholar] [CrossRef]
- Itokawa, K.; Sekizuka, T.; Hashino, M.; Tanaka, R.; Kuroda, M. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. PLoS ONE 2020, 15, e0239403. [Google Scholar] [CrossRef]
- Sekizuka, T.; Itokawa, K.; Hashino, M.; Kawano-Sugaya, T.; Tanaka, R.; Yatsu, K.; Ohnishi, A.; Goto, K.; Tsukagoshi, H.; Ehara, H.; et al. A Genome Epidemiological Study of SARS-CoV-2 Introduction into Japan. mSphere 2020, 5, e00786-20. [Google Scholar] [CrossRef]
- Shu, Y.; McCauley, J. GISAID: Global initiative on sharing all influenza data—From vision to reality. Eurosurveillance 2017, 22, 30494. [Google Scholar] [CrossRef] [Green Version]
- Tarhini, H.; Recoing, A.; Bridier-Nahmias, A.; Rahi, M.; Lambert, C.; Martres, P.; Lucet, J.C.; Rioux, C.; Bouzid, D.; Lebourgeois, S.; et al. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. J. Infect. Dis. 2021, 223, 1522–1527. [Google Scholar] [CrossRef]
- Avanzato, V.A.; Matson, M.J.; Seifert, S.N.; Pryce, R.; Williamson, B.N.; Anzick, S.L.; Barbian, K.; Judson, S.D.; Fischer, E.R.; Martens, C.; et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 2020, 183, 1901–1912.e9. [Google Scholar] [CrossRef]
- Camprubí, D.; Gaya, A.; Marcos, M.A.; Martí-Soler, H.; Soriano, A.; del Mar Mosquera, M.; Oliver, A.; Santos, M.; Muñoz, J.; García-Vidal, C. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Int. J. Infect. Dis. 2021, 104, 379–381. [Google Scholar] [CrossRef] [PubMed]
- Sepulcri, C.; Dentone, C.; Mikulska, M.; Bruzzone, B.; Lai, A.; Fenoglio, D.; Bozzano, F.; Bergna, A.; Parodi, A.; Altosole, T.; et al. The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. Open Forum Infect Dis. 2021, 8, ofab217. [Google Scholar] [CrossRef] [PubMed]
- Aydillo, T.; Gonzalez-Reiche, A.S.; Aslam, S.; van de Guchte, A.; Khan, Z.; Obla, A.; Dutta, J.; van Bakel, H.; Aberg, J.; García-Sastre, A.; et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N. Engl. J. Med. 2020, 383, 2586–2588. [Google Scholar] [CrossRef] [PubMed]
- Epstein, R.L.; Sperring, H.; Hofman, M.; Lodi, S.; White, L.F.; Barocas, J.A.; Bouton, T.C.; Xiao, Y.; Hsu, H.E.; Miller, N.S.; et al. Time to SARS-CoV-2 PCR Clearance in Immunocompromising Conditions: Is Test-Based Removal From Isolation Necessary in Severely Immunocompromised Individuals? Open Forum. Infect. Dis. 2021, 8, ofab164. [Google Scholar] [CrossRef]
- García, L.F. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front. Immunol. 2020, 11, 1441. [Google Scholar] [CrossRef]
- Arora, K.; Panda, P.K. Steroid harms if given early in COVID-19 viraemia. BMJ Case Rep. 2021, 14, e241105. [Google Scholar] [CrossRef]
- Fishman, J.A.; Grossi, P.A. Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. Am. J. Transplant. 2020, 20, 1765–1767. [Google Scholar]
- Passamonti, F.; Cattaneo, C.; Arcaini, L.; Bruna, R.; Cavo, M.; Merli, F.; Angelucci, E.; Krampera, M.; Cairoli, R.; Della Porta, M.G.; et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study. Lancet Haematol. 2020, 7, e737–e745. [Google Scholar] [CrossRef]
- Jacobs, C.F.; Eldering, E.; Kater, A.P. Kinase inhibitors developed for treatment of hematologic malignancies: Implications for immune modulation in COVID-19. Blood Adv. 2021, 5, 913–925. [Google Scholar] [CrossRef]
- Davids, M.S.; Brown, J.R. Ibrutinib: A first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 2014, 10, 957–967. [Google Scholar] [CrossRef] [PubMed]
- Kifle, Z.D. Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review. Metab. Open 2021, 11, 100116. [Google Scholar] [CrossRef] [PubMed]
- Chung, D.J.; Shah, G.L.; Devlin, S.M.; Ramanathan, L.V.; Doddi, S.; Pessin, M.S.; Hoover, E.; Marcello, L.T.; Young, J.C.; Boutemine, S.R.; et al. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discov. 2021, 2, 568–576. [Google Scholar] [CrossRef] [PubMed]
- Gagelmann, N.; Passamonti, F.; Wolschke, C.; Massoud, R.; Niederwieser, C.; Adjallé, R.; Mora, B.; Ayuk, F.; Kröger, N. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: A systematic review and meta-analysis. Haematologica 2022, 107, 1840–1849. [Google Scholar] [CrossRef]
- Fontana, L.M.; Villamagna, A.H.; Sikka, M.K.; McGregor, J.C. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. Infect. Control Hosp. Epidemiol. 2021, 42, 659–668. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nagasaki, Y.; Kadowaki, M.; Nakamura, A.; Etoh, Y.; Shimo, M.; Ishihara, S.; Arimizu, Y.; Iwamoto, R.; Kamamuta, S.; Iwasaki, H. A Case of a Malignant Lymphoma Patient Persistently Infected with SARS-CoV-2 for More than 6 Months. Medicina 2023, 59, 108. https://doi.org/10.3390/medicina59010108
Nagasaki Y, Kadowaki M, Nakamura A, Etoh Y, Shimo M, Ishihara S, Arimizu Y, Iwamoto R, Kamamuta S, Iwasaki H. A Case of a Malignant Lymphoma Patient Persistently Infected with SARS-CoV-2 for More than 6 Months. Medicina. 2023; 59(1):108. https://doi.org/10.3390/medicina59010108
Chicago/Turabian StyleNagasaki, Yoji, Masanori Kadowaki, Asako Nakamura, Yoshiki Etoh, Masatoshi Shimo, Sayoko Ishihara, Yoko Arimizu, Rena Iwamoto, Seiji Kamamuta, and Hiromi Iwasaki. 2023. "A Case of a Malignant Lymphoma Patient Persistently Infected with SARS-CoV-2 for More than 6 Months" Medicina 59, no. 1: 108. https://doi.org/10.3390/medicina59010108